Quay lại Không gian tin tức
Tin tức từ The United Laboratories International Holdings Limited
#Healthcare
#Medical
25 March 2026 2:00pm HKT
Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes
#Medical
#Finance
24 February 2026 5:00pm HKT
Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China
#Medical
#Pharma
24 March 2025 7:25pm HKT
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
#Pharma
#Medical
20 June 2023 3:15pm HKT
The United Laboratories International Holdings Limited Applies for the Clinical Trial of its Class 1 Innovative New Drug UBT251 Injection
#Business
14 May 2017 2:00pm HKT